Fidelis Capital Partners’s Insmed INSM Stock Holding History

Fidelis Capital Partners’s Portfolio INSM Stock Details INSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,325	Closed	-$217K	–	545
2026 Q1	$217K	Buy	1,325 +54	+4%	+$8.3K	0.02%	469
2025 Q4	$221K	Buy	+1,271	New	+$232K	0.02%	456

Other funds holding INSM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Fidelis Capital Partners's INSM Position: Q2 2026 in Review

Fidelis Capital Partners sold out of Insmed (INSM) in Q2 2026, closing a stake of 1,325 shares — an estimated $217K sold.

Fidelis Capital Partners first reported a position in INSM in Q4 2025 and held it in 2 quarters. The position peaked at $221K in Q4 2025. 665 funds tracked by Wall St. Rank hold INSM as of Q2 2026.

Fidelis Capital Partners reported no remaining Insmed position as of Q2 2026 after selling out during the quarter.
Fidelis Capital Partners sold 1,325 Insmed shares in Q2 2026, an estimated $217K.
Fidelis Capital Partners first reported a position in Insmed in Q4 2025 and held it in 2 quarters.
Fidelis Capital Partners's Insmed position peaked at $221K in Q4 2025.
665 funds tracked by Wall St. Rank held Insmed as of Q2 2026.

Based on Fidelis Capital Partners's 13F filing for Q2 2026, filed 13 Aug 2026.